TAK-573, an anti-CD38-targeted attenuated interferon alpha (IFNα) fusion protein, showed anti-myeloma tumor responses in combination with standard of care (SOC) agents in multiple myeloma (MM) xenograft tumor models in vivo

Abstract

Even with transformative therapies, multiple myeloma is a relapsing and ultimately fatal disease. We previously reported that targeting an attenuated form of IFNα, or Attenukine™, to MM tumor cells via direct fusion to an anti-CD38 antibody (TAK-573) has direct anti-proliferative activity on MM cancer cells in vitro and induces robust and durable responses in MM xenograft tumor models. Here we demonstrate the anti-tumor impact of TAK-573, alone and in combination with SOC agents in MM xenograft tumor models in vivo.